Health Related Quality of Life in Iron Deficient Heart Transplant Recipients Receiving Intravenous Iron Supplement: A Prespecified Secondary Endpoint in the IronIC Trial
| Autor: | Lars Gullestad, Arne K. Andreassen, Einar Gude, C.M. Oestby, K.V. Brautaset Englund, Kaspar Broch, Katrine Rolid |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Health related quality of life Transplantation medicine.medical_specialty biology business.industry Minimal clinically important difference Intravenous iron Iron deficiency medicine.disease Placebo humanities Ferritin Quality of life Heart failure Internal medicine medicine biology.protein Surgery Cardiology and Cardiovascular Medicine business |
| Zdroj: | The Journal of Heart and Lung Transplantation. 40:S281-S282 |
| ISSN: | 1053-2498 |
| DOI: | 10.1016/j.healun.2021.01.800 |
| Popis: | Purpose Health related quality of life (HRQoL) is reduced in heart transplant (HTx) recipients compared to that of healthy individuals. Intravenous iron supplement improves quality of life in patients with heart failure and iron deficiency (ID). The IronIC trial was designed to test if a single dose of ferric derisomaltose, formerly known as iron isomaltoside, could improve exercise capacity in HTx recipients. HRQoL was a prespecified secondary endpoint. Methods In the IronIC trial we randomized 102 HTx recipients with ID to ferric derisomaltose or placebo. ID was defined as ferritin Results There was no between-group difference in peak oxygen consumption in the IronIC trial. However, HRQoL was improved in the ferric derisomaltose group compared to controls at follow-up. A significant between group difference was found in the EQ-5D index (Figure 1A), the EQ-5D-VAS (Figure 1B), and the SF-36 MCS (Figure 1C). The SF-36 MCS MCID was also significant. The SF-36 PCS (Figure 1D) and the SF-36 PCS MCID were not significantly different between the groups at follow up. Conclusion The prespecified secondary outcome HRQoL was better in the ferric derisomaltose group. These findings suggest a possible approach to improve HRQoL in HTx recipients, and could provide the basis for a trial designed to assess this issue. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|